Insider Buying: Microbix Biosystems (TSE:MBX) Director Buys 69,000 Shares of Stock

Microbix Biosystems Inc. (TSE:MBX) Director Martin Marino acquired 69,000 shares of the company’s stock in a transaction on Tuesday, May 26th. The shares were bought at an average cost of C$0.26 per share, with a total value of C$17,940.00. Following the acquisition, the director directly owned 1,860,667 shares in the company, valued at approximately C$483,773.42. The trade was a 3.85% increase in their ownership of the stock.

Martin Marino also recently made the following trade(s):

• On Wednesday, May 27th, Martin Marino bought 24,500 shares of Microbix Biosystems stock. The shares were purchased at an average price of C$0.26 per share, with a total value of C$6,370.00.

Microbix Biosystems Trading Down 1.8%

TSE:MBX traded down C$0.01 during midday trading on Thursday, hitting C$0.28. 94,500 shares of the company traded hands, compared to its average volume of 61,453. The firm’s fifty day moving average is C$0.24 and its 200-day moving average is C$0.24. Microbix Biosystems Inc. has a 12-month low of C$0.21 and a 12-month high of C$0.34. The firm has a market capitalization of C$37.81 million, a P/E ratio of -6.71 and a beta of 0.48. The company has a current ratio of 5.35, a quick ratio of 5.57 and a debt-to-equity ratio of 27.03.

Microbix Biosystems (TSE:MBX) last posted its quarterly earnings data on Thursday, May 14th. The company reported C($0.01) earnings per share for the quarter. Microbix Biosystems had a negative return on equity of 21.02% and a negative net margin of 38.62%.The firm had revenue of C$3.38 million during the quarter. On average, sell-side analysts predict that Microbix Biosystems Inc. will post 0.02 EPS for the current year.

About Microbix Biosystems

Microbix develops proprietary biological technology solutions for human health and well-being, with about 90 skilled employees and sales growing from a base of over $1 million per month. It makes a wide range of critical biological materials for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows.